Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Cigna (CI) Q3 Earnings & Revenues Beat Estimates, Grow Y/Y

By Zacks Investment ResearchStock MarketsNov 05, 2020 01:15AM ET
www.investing.com/analysis/cigna-ci-q3-earnings--revenues-beat-estimates-grow-yy-200543651
Cigna (CI) Q3 Earnings & Revenues Beat Estimates, Grow Y/Y
By Zacks Investment Research   |  Nov 05, 2020 01:15AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Cigna Corp.’s CI third-quarter 2020 earnings of $4.41 per share surpassed the Zacks Consensus Estimate by 3.7% and also grew 5.8% year over year.

Results reflected a strong fundamental performance across its businesses as well as the return of the medical utilization to more typical levels and the COVID-19 related impacts.

Cigna’s revenues of $40.8 billion beat the Zacks Consensus Estimate by 4.3% and also increased 13.9% year over year, driven by a higher contribution from its businesses led by its Evernorth segment.

The company saw a decline of 89000 customers from the prior-year quarter in its medical enrollment customers to 16.892 million customers, attributable to lower commercial members.

Selling, general and administrative expense ratio was 8.1, which improved 110 basis points year over year on significant growth in revenues and cost-control measures.

Strong Segmental Performances

Evernorth Health Services: During the quarter, the company rebranded its Health Services segment under Evernorth. The same includes pharmacy benefit manager Express Scripts (NASDAQ:ESRX), specialty pharmacy Accredo and eviCore healthcare, which provides utilization management services for health plans or employer groups and outpatient diagnostic imaging service programs.

Adjusted revenues of $29.8 billion were up 19.9% year over year, driven by the insourcing of U.S. Medical pharmacy volumes and strong organic growth including growth in retail network and specialty pharmacy services.
Operating income of $1.44 billion increased 3.1% year over year, reflecting customer growth, higher adjusted pharmacy scripts volumes, benefits from the effective management of the supply chain and a continued strong performance in specialty pharmacy services, partially offset by higher operating expenses to support growth.

During the quarter, Evernorth fulfilled 381 million adjusted pharmacy, up 22% year over year, driven by the insourcing of U.S. Medical pharmacy volumes and strong organic growth.

U.S. Medical: Earlier called Integrated medical, this segment was renamed in this quarter and reported adjusted revenues of $9.63 billion, up 5.3% year over year, highlighting customer wins in Medicare Advantage as well as in the Select segment, besides premium growth.

Operating income of $757 million declined 20.6% year over year due to the impact of the return of medical utilization to more typical levels and direct COVID-19 costs as apart from the costs involving strategic actions taken by the company to support customers and providers. Additionally, decreased specialty contributions and lower net investment income induced this downside.

International Markets: Adjusted revenues of $1.44 billion were up 2.7% year over year, reflecting consistent business growth.
Operating earnings of $208 million were up 7.2% year over year, boosted by a consistent operational efficiency, lower claim levels, driven by the effects of the COVID-19 pandemic, and business growth.

Group Disability and Other Operations: Adjusted revenues of $1.31 billion inched up 2.3% year over year. Operating earnings of $70 million were down 51% year over year, reflecting elevated claims in Cigna’s Life business, primarily related to the COVID-19 pandemic. This segment is on track to be sold to New York Life. Cigna expects the transaction to close in the fourth quarter of 2020.

Capital Position

Cigna’s debt-to-capitalization ratio improved to 42.8 as of Sep 30, 2020 from 45.2 as of Dec 31, 2019.
Shareholders’ equity as of Sep 30, 2020 was $48 billion, up 7.5% year over year.

2020 Guidance

The company’s earlier-issued outlook for full-year revenues was raised to be nearly $158 billion, up from the prior view of $154-$156 billion.

The lower end of the earlier-issued earnings projection was lifted to the $18.3-$18.6 per share from $18-$18.6 as envisaged earlier.

Our Take

Cigna's consistent rise in revenues and profits are impressive. The acquisition of Express Scripts bodes well for the long haul. The company is divesting its Group Life and Disability insurance business, which will reduce its debt level and streamline the business operations. Its expanding international business provides diversification. Its operating profitability achieved by a controlled medical care cost and other operating costs has been aiding its bottom line. The company’s upped earnings guidance despite the COVID-19-led uncertainty boosts investor confidence in the stock.

Some other players in the same space that already reported third-quarter earnings and surpassed the respective Zacks Consensus Estimate are UnitedHealth Group Inc. UNH, Anthem Inc ANTM and Humana Inc (NYSE:HUM). HUM.

Cigna carries a Zacks Rank #2, currently. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>




Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

UnitedHealth Group Incorporated (NYSE:UNH): Free Stock Analysis Report

Humana Inc. (HUM): Free Stock Analysis Report

Cigna Corporation (CI): Free Stock Analysis Report

Anthem, Inc. (ANTM): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
Cigna (CI) Q3 Earnings & Revenues Beat Estimates, Grow Y/Y
 

Related Articles

Cigna (CI) Q3 Earnings & Revenues Beat Estimates, Grow Y/Y

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email